Bayer issues new senior bonds with a volume of 6 billion euros
Issuance of four tranches with maturities between 4 and 12 years was substantially oversubscribed (Source: Bayer Company News)
Source: Bayer Company News - July 1, 2020 Category: Pharmaceuticals Source Type: news

Bayer announces agreements to resolve major legacy Monsanto litigation
Company will make a total payment of $10.1 billion to $10.9 billion (EUR 9.1 billion to EUR 9.8 billion) to resolve current and address potential future Roundup™ litigation / Company also resolves dicamba drift litigation for payment of up to $400 million and most PCB water litigation exposure for payment of approximately $820 million / Funding sourced from free cash flow and Animal Health divestment / Bayer is well positioned to deliver science-based solutions to meet global health, nutrition needs (Source: Bayer Company News)
Source: Bayer Company News - June 24, 2020 Category: Pharmaceuticals Source Type: news

Bayer to Provide Crop Relief to Two Million Smallholder Farmers Impacted by COVID-19
Through its new“Better Farms, Better Lives” initiative, Bayer will complement its current commitment to support smallholder farmers in key countries by donating seeds and crop protection inputs / The donations help boost food security by supporting up to two million smallholder farmers facing increased challenges as a result of the on-going COVID-19 pandemic (Source: Bayer Company News)
Source: Bayer Company News - June 17, 2020 Category: Pharmaceuticals Source Type: news

Bayer extends clinical development program for finerenone with Phase III study in patients with heart failure and preserved ejection fraction (for specialized target groups only)
FINEARTS-HF is the first large-scale, long-term study to investigate the non-steroidal, selective mineralocorticoid receptor antagonist finerenone on morbidity and mortality outcomes in a heart failure patient population (Source: Bayer Company News)
Source: Bayer Company News - June 15, 2020 Category: Pharmaceuticals Source Type: news

Bayer submits vericiguat for marketing authorization in the EU and Japan for the treatment of chronic heart failure (for specialized target groups only)
Regulatory submissions based on positive data from Phase III VICTORIA study recently published in the New England Journal of Medicine (1) (Source: Bayer Company News)
Source: Bayer Company News - June 5, 2020 Category: Pharmaceuticals Source Type: news

Bayer submits larotrectinib for marketing authorization in Japan for the treatment of TRK fusion cancer (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - May 22, 2020 Category: Pharmaceuticals Source Type: news

Independent external council to advise Bayer ’ s Board of Management on consistent implementation of its sustainability targets
(Source: Bayer Company News)
Source: Bayer Company News - May 19, 2020 Category: Pharmaceuticals Source Type: news

Nubeqa ™ (darolutamide) significantly improved overall survival with a favorable safety profile in men with non-metastatic prostate cancer (for specialized target groups only)
Darolutamide significantly reduced risk of death by 31 percent (HR=0.69, 95% CI 0.53-0.88; p=0.003) in men with non-metastatic castration-resistant prostate cancer (nmCRPC) / Darolutamide significantly delayed the time to pain progression, time to first initiation of cytotoxic chemotherapy, and time to first symptomatic skeletal event (SSE) / Darolutamide continues to demonstrate a favorable safety profile, with no new safety signals observed, even with a longer treatment duration, allowing men with nmCRPC to maintain their active lifestyle / ARAMIS data will be presented at the American Society of Clinical Oncology (ASCO)...
Source: Bayer Company News - May 13, 2020 Category: Pharmaceuticals Source Type: news

“ We ’ re active in the right businesses ”
Coronavirus crisis: Employee safety at the top of the agenda / First DAX company to hold virtual stockholders’ meeting / Strategic and operational targets attained in 2019 / Dividend of 2.80 euros per share proposed / Good start to fiscal 2020 / Winkeljohann to succeed Wenning as Supervisory Board Chairman (Source: Bayer Company News)
Source: Bayer Company News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Bayer: Good start to 2020 – activities marked by COVID-19
Employee safety and business continuity are top priorities / Wide-ranging humanitarian and social engagement / Group sales increase by 6.0 percent (Fx& portfolio adj.) to 12.845 billion euros / EBITDA before special items up by 10.2 percent to 4.391 billion euros / All divisions report higher sales and earnings– strong demand at Consumer Health / Net income advances by 20.0 percent to 1.489 billion euros / Core earnings per share increase by 9.9 percent to 2.67 euros / Outlook for 2020: impact of COVID-19 not yet reliably quantifiable (Source: Bayer Company News)
Source: Bayer Company News - April 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer partners with Population Health Research Institute (PHRI) on global clinical research evaluating COVID-19 treatments
Investigation of combination therapies including Bayer’s chloroquine and interferon beta-1b to foster much needed solutions for patients in fight against coronavirus pandemic / Bayer Canada to make CAD 1.5 million (approximately 1 million euros) financial commitment and to supply products in support of the research / Plans to include more than 60 contributing research locations involving 6.000 patients (Source: Bayer Company News)
Source: Bayer Company News - April 21, 2020 Category: Pharmaceuticals Source Type: news

Bayer donates 8 million chloroquine tablets to the German Federal Government
Additional donations of chloroquine sent to governments in numerous other countries / Various clinical and preclinical studies investigate the efficacy and adverse effects in COVID-19 infections / Bayer plans considerable expansion of production capacities in the event that the efficacy of chloroquine is proven for COVID-19 (Source: Bayer Company News)
Source: Bayer Company News - April 14, 2020 Category: Pharmaceuticals Source Type: news

Bayer launches pre-filled syringe to administer eye medication Eylea ™ in Europe (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - April 8, 2020 Category: Pharmaceuticals Source Type: news

Bayer launches pre-filled syringe to administer eye medication Eylea ® in Europe (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - April 8, 2020 Category: Pharmaceuticals Source Type: news

Nubeqa ™ (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Oral androgen receptor inhibitor (ARi) Nubeqa™ (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free survival (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile (Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news

Nubeqa ® (darolutamide) receives EU approval as a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Oral androgen receptor inhibitor (ARi) Nubeqa ® (darolutamide) approved for the treatment of men with non-metastatic castration-resistant prostate cancer (nmCRPC), who are at high risk of developing metastatic disease / Approval is based on Phase III ARAMIS trial results showing a statistically significant improvement in metastasis-free surviv al (MFS) for darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT, and a favorable safety profile (Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news

Bayer to boost Germany ’ s COVID-19 analysis capacity by several thousand tests per day
(Source: Bayer Company News)
Source: Bayer Company News - March 30, 2020 Category: Pharmaceuticals Source Type: news

Bayer planning to hold online-only stockholders ’ meeting on April 28, 2020
Stockholders able to exercise right to submit questions and cast votes in a timely manner / Online stockholders’ meeting enables proposed dividend of 2.80 euros per share for 2019 to be paid on time and in full / Baumann:“Reliability for our stockholders is very important, especially during the crisis” (Source: Bayer Company News)
Source: Bayer Company News - March 27, 2020 Category: Pharmaceuticals Source Type: news

Bayer announces five late-breaking presentations which include data from VICTORIA (vericiguat) and VOYAGER PAD (Xarelto ™ ) Phase III studies (for specialized target groups only)
The VICTORIA study provides insight into the efficacy of vericiguat, the first soluble guanylate cyclase (sGC) stimulator investigated in patients with chronic heart failure following a worsening event / The VOYAGER PAD study investigated the use of Xarelto 2.5 mg twice daily plus aspirin 100 mg once daily in patients with symptomatic peripheral artery disease (PAD) post peripheral revascularization / Five late-breaking abstracts have been accepted for presentation and demonstrate Bayer’s ongoing commitment to the treatment of cardiovascular disease (Source: Bayer Company News)
Source: Bayer Company News - March 20, 2020 Category: Pharmaceuticals Source Type: news

Bayer donates one million euros for hospitals in Lombardy
Chairman of the Board of Management, Baumann:“Our emergency aid is designed to help support hospitals and hospital staff during the crisis.” (Source: Bayer Company News)
Source: Bayer Company News - March 18, 2020 Category: Pharmaceuticals Source Type: news

Bayer strategically and operationally successful
Group sales advance by 3.5 percent (Fx& portfolio adj.) to 43.545 billion euros / EBITDA before special items increases by 28.3 percent to 11.503 billion euros / Core earnings per share up by 14.3 percent to 6.40 euros / Net income rises 141.4 percent to 4.091 billion euros– gain of 1.637 billion euros on sale of Currenta stake / Free cash flow of 4.214 billion euros above expectations / Proposed dividend of 2.80 euros per share / Crop Science shows solid performance in challenging environment, substantial increase in earnings due to acquired business / Pharmaceuticals shows encouraging business development / Sal...
Source: Bayer Company News - February 27, 2020 Category: Pharmaceuticals Source Type: news

Norbert Winkeljohann to succeed Werner Wenning as Chairman of Bayer ’ s Supervisory Board
Werner Wenning to retire after over 50 years with Bayer / Horst Baier proposed for election as new shareholder representative (Source: Bayer Company News)
Source: Bayer Company News - February 26, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Nuvisan create new research unit in Berlin
Nuvisan to establish full-fledged research center with around 400 jobs in Berlin / Transaction to contribute to further strengthening healthcare cluster in Berlin / Bayer to retain significant research activities and headquarters for the company’s Pharmaceuticals Division in Berlin (Source: Bayer Company News)
Source: Bayer Company News - February 11, 2020 Category: Pharmaceuticals Source Type: news

CDP again rates Bayer as one of the leading international companies for water management
Top assessment for 10 years in succession / Bayer only DAX company with best rating both in climate change and water security (Source: Bayer Company News)
Source: Bayer Company News - February 3, 2020 Category: Pharmaceuticals Source Type: news

Bayer application for nifurtimox to treat pediatric patients with Chagas disease submitted for approval in US
New formulation for weight-adjusted treatment of pediatric Chagas patients age 0-18 targets most vulnerable patient group / Submission based on results of CHICO (CHagas disease In Children treated with NifurtimOx) phase III clinical study of nifurtimox in pediatric patients with Chagas disease as well as pre-clinical data / Fight against Neglected Tropical Diseases part of Bayer’s Sustainability Strategy (Source: Bayer Company News)
Source: Bayer Company News - January 30, 2020 Category: Pharmaceuticals Source Type: news

Darolutamide plus androgen deprivation therapy significantly increased overall survival in men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Full data to be presented at upcoming scientific meeting (Source: Bayer Company News)
Source: Bayer Company News - January 30, 2020 Category: Pharmaceuticals Source Type: news

Bayer to donate medicines and money with a total value of approximately EUR 1.5 million
CEO Werner Baumann:“We want to help people in the affected regions quickly and effectively” (Source: Bayer Company News)
Source: Bayer Company News - January 28, 2020 Category: Pharmaceuticals Source Type: news

Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea ® (for specialized target groups only)
(Source: Bayer Company News)
Source: Bayer Company News - January 23, 2020 Category: Pharmaceuticals Source Type: news

Bayer receives approval for darolutamide in Japan (for specialized target groups only)
Marketing authorization granted for the treatment of men with non-metastatic castration-resistant prostate cancer (Source: Bayer Company News)
Source: Bayer Company News - January 23, 2020 Category: Pharmaceuticals Source Type: news

Bayer and Dar é Bioscience enter into exclusive license agreement for U.S. commercial rights to investigational hormone-free, monthly contraceptive Ovaprene® (for specialized target groups only)
Underlining Bayer’s commitment in the field of women’s health / Potential commercial milestone payments of up to USD 310 million and tiered royalties on net sales in the double-digit range (Source: Bayer Company News)
Source: Bayer Company News - January 13, 2020 Category: Pharmaceuticals Source Type: news

Bayer to significantly step-up its sustainability efforts
2030 target to be carbon neutral in own operations / Ambitious 2030 objectives for access to health and nutrition in low- and middle-income countries and underserved communities / Measurable sustainability targets to be incorporated into management compensation (Source: Bayer Company News)
Source: Bayer Company News - December 10, 2019 Category: Pharmaceuticals Source Type: news

Bayer completes sale of Currenta stake to Macquarie Infrastructure and Real Assets
Further step in Bayer’s efforts to sharpen focus on core business (Source: Bayer Company News)
Source: Bayer Company News - November 29, 2019 Category: Pharmaceuticals Source Type: news

Bayer submits application to EMA for use of rivaroxaban in children with venous thromboembolism (for specialized target groups only)
Adding treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children from birth to 17 years of age with confirmed VTE, including cerebral vein and sinus thrombosis / Submission based on results from phase 3 EINSTEIN-Jr. study showing convincing efficacy and safety profile for rivaroxaban in children with VTE / An oral liquid formulation of rivaroxaban that does not require injections and regular monitoring was developed to facilitate pediatric administration / Patent extension in Europe of six months will be applied for once the procedure is completed (Source: Bayer Company News)
Source: Bayer Company News - November 25, 2019 Category: Pharmaceuticals Source Type: news

Phase III VICTORIA study with vericiguat in patients with worsening chronic heart failure meets primary endpoint (for specialized target groups only)
Vericiguat reduced the risk of cardiovascular death or heart failure hospitalization versus placebo when given in combination with available heart failure therapies / Vericiguat is the first-in-class soluble guanylate cyclase stimulator being developed to treat patients with worsening chronic heart failure (Source: Bayer Company News)
Source: Bayer Company News - November 18, 2019 Category: Pharmaceuticals Source Type: news

Bayer refinances 1.75 billion euro hybrid bond
New issue of two tranches with a non-call period of 5.5 and 8 years combined with a tender offer for Bayer’s existing hybrid bond (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2019 Category: Pharmaceuticals Source Type: news

Bayer invests USD 50 Million in eGenesis Series B financing round
Investment to support development of human-compatible xeno organs to address the global organ shortage crisis / eGenesis with lead program in kidney transplantation (Source: Bayer Company News)
Source: Bayer Company News - November 7, 2019 Category: Pharmaceuticals Source Type: news

Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health
Group sales increase by 5.4 percent (Fx& portfolio adj.) to 9.830 billion euros / EBITDA before special items advances by 7.5 percent to 2.291 billion euros / Crop Science reports higher sales and substantial earnings growth / Pharmaceuticals increases sales – earnings decline due to one-time income in prior year / Consumer Health posts growth in sales (Fx& portfolio adj.) and earnings / Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year / Core earnings per share up by 6.4 percent to 1.16 euros / Group outlook confirmed and aligned to continui...
Source: Bayer Company News - October 30, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA approves rivaroxaban to help prevent blood clots in acutely ill medical patients (for specialized target groups only)
A new oral option for patients in the U.S. with acute medical illnesses at risk for thromboembolic complications who are not at high risk of bleeding / Rivaroxaban is the only non vitamin K antagonist oral anticoagulant (NOAC) approved in the U.S for the continuum of venous thromboembolism (VTE) care, from prevention and treatment of initial VTE through extended prevention of recurrent VTE (Source: Bayer Company News)
Source: Bayer Company News - October 14, 2019 Category: Pharmaceuticals Source Type: news

Ertharin Cousin to become member of Bayer AG Supervisory Board
International expert in the area of nutrition and agriculture / Cousin succeeds Thomas Ebeling, who stepped down at the end of September (Source: Bayer Company News)
Source: Bayer Company News - October 1, 2019 Category: Pharmaceuticals Source Type: news

Updated analysis for larotrectinib confirms high response rate and durable responses over three years in children and adults with TRK fusion cancer (for specialized target groups only)
79% overall response rate (ORR) in 153 evaluable adult and pediatric patients at time of new data cut off (February 19, 2019); results consistent with previous publications(1,2) / Similar ORR of 75% in patients with brain metastases(1), adding to the previously reported evidence for larotrectinib’s activity in central nervous system (CNS) / Median progression free survival (mPFS) of 28.3 months and median overall survival (mOS) of more than three years (44.4 months) was achieved; median duration of response (mDOR) of nearly three years(1) / Largest dataset with longest follow-up of any TRK inhibitor illustrates favor...
Source: Bayer Company News - September 28, 2019 Category: Pharmaceuticals Source Type: news

Vitrakvi ® (larotrectinib) receives first tumor-agnostic approval in EU (for specialized target groups only)
Precision oncology treatment Vitrakvi ® (larotrectinib) approved for the treatment of adults and children with locally advanced or metastatic solid tumors that have a rare genomic alteration called an NTRK gene fusion / Vitrakvi, which was exclusively designed to treat TRK fusion cancer, is the first therapy in the EU with a tumor-agno stic indication / Larotrectinib provides high response rates and durable responses in adults and children with TRK fusion cancer, including primary CNS tumors and brain metastases / In studies, larotrectinib demonstrated an overall response rate of 72% including 16% complete responses, w...
Source: Bayer Company News - September 23, 2019 Category: Pharmaceuticals Source Type: news

Bayer reduces size of Board of Management from seven to five members
(Source: Bayer Company News)
Source: Bayer Company News - September 10, 2019 Category: Pharmaceuticals Source Type: news

Xarelto & #8482; 2.5 mg plus aspirin recommended for patients at high risk of heart attacks, strokes and death due to chronic coronary syndromes
Clinical practice guidelines from the European Society of Cardiology (ESC) recommend Xarelto vascular dose (2.5 mg twice daily) plus aspirin low dose once daily in the management of patients with chronic coronary syndromes (CCS) as well as for patients with diabetes and lower extremity arterial disease / New guidelines include a change in nomenclature from‘stable coronary artery disease’ to‘chronic coronary syndromes’ to better reflect the continuous high risk of heart attacks, strokes and death within this patient population (Source: Bayer Company News)
Source: Bayer Company News - September 2, 2019 Category: Pharmaceuticals Source Type: news

Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences (Source: Bayer Company News)
Source: Bayer Company News - August 20, 2019 Category: Pharmaceuticals Source Type: news

Bayer to sell its Animal Health business unit to Elanco for 7.6 billion U.S. dollars
Exit of Animal Health business completes the series of portfolio measures initiated by Bayer in November 2018 ahead of announced schedule / Enhances Bayer’s focus as a global leader in life sciences (Source: Bayer Company News)
Source: Bayer Company News - August 20, 2019 Category: Pharmaceuticals Source Type: news

Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
Implied total company value of up to USD 1 billion, inclusive of 40.8 percent stake currently held by Bayer / Initial focus in neurology, cardiology, and immunology with start of first clinical program in Parkinson’s disease expected later this year / BlueRock Therapeutics to continue to operate as an independent company (Source: Bayer Company News)
Source: Bayer Company News - August 8, 2019 Category: Pharmaceuticals Source Type: news

Bayer and LANXESS to sell their stakes in Currenta to Macquarie Infrastructure and Real Assets
Currenta valued with an attractive enterprise value of EUR 3.5 billion (100%) (Source: Bayer Company News)
Source: Bayer Company News - August 6, 2019 Category: Pharmaceuticals Source Type: news

U.S. FDA approves darolutamide, a new treatment for men with non-metastatic castration-resistant prostate cancer (for specialized target groups only)
Darolutamide was approved in the U.S. under the FDA Priority Review designation; approval granted three months ahead of target FDA action date / Approval based on Phase III ARAMIS trial evaluating the efficacy and safety of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT (Source: Bayer Company News)
Source: Bayer Company News - July 31, 2019 Category: Pharmaceuticals Source Type: news

Bayer on track in operational business
Group sales increase by 0.9 percent (Fx& portfolio adj.) to 11.485 billion euros / EBITDA before special items advances by 24.7 percent to 2.927 billion euros / Crop Science sees sales decline (Fx& portfolio adj. and pro forma) in challenging environment but posts substantial earnings growth due to acquired business / Pharmaceuticals posts higher sales and strong earnings growth / Consumer Health increases sales and earnings / Net income falls by 49.1 percent to 404 million euros, held back by special items for restructuring and impairments / Core earnings per share increase by 5.9 percent to 1.62 euros / Group out...
Source: Bayer Company News - July 30, 2019 Category: Pharmaceuticals Source Type: news